Why is Travere Therapeutics stock sliding today?
Travere Therapeutics (TVTX) shares fell 4.3% in pre-market trading after reporting Q3 2026 results. The company missed earnings estimates due to a $113.1M R&D expense, despite revenue beating expectations. Leerink Partners cut its price target to $67 from $78. CEO Eric Dube sold shares in mid-October. FILSPARI sales grew 120% YoY, but Q4 inventory normalization may impact revenue.
How this was made
The 30-second read
Why it matters
The dominant driver is a large IPR&D expense tied to the civorebrutinib licensing and collaboration agreement, which overwhelms the revenue beat. Additional pressure comes from a same-day analyst price target cut and an expected reversal of elevated specialty-pharmacy inventory affecting Q3 sales.
Market read
Traders get a same-day catalyst bundle: quantified earnings miss mechanics, a PT cut, and a specific Q4 inventory headwind, all explaining the pre-market selloff.
What to watch
The article notes CEO stock sales and a December leadership transition; traders may be over-weighting these signals versus the magnitude and timing of the Q4 inventory normalization.
Background
Travere Therapeutics reported Q3 2026 results after the prior close, and the stock is trading lower in pre-open as investors focus on an earnings miss and forward inventory normalization risk.
Ticker impact
Travere Therapeutics shares slide 4.3% pre-open after Q3 2026 results show an adjusted loss of $0.55 vs consensus profit, driven by a $113.1M IPR&D charge tied to civorebrutinib licensing with Everest Medicines.
Likely further pressure as investors reprice the quality of earnings and weigh the Q4 inventory headwind against strong FILSPARI sales.
The article attributes the move to the company’s own earnings miss, quantifies the charge, cites a same-day PT cut, and flags a specific forward headwind (inventory normalization).
Market effects
Reinforces that biotech investors are penalizing large non-recurring pipeline charges even when revenue beats.
No clear broad-market driver; futures are mixed, suggesting idiosyncratic risk-off in TVTX.
Limited, as the catalyst is company-specific earnings and analyst reaction.
Counterpoint
The revenue beat and strong FILSPARI net product sales growth (120% YoY) could support a rebound if investors treat the IPR&D charge as non-recurring and focus on commercial momentum.
Key entities
- companyTravere Therapeutics
Subject of the article, with Q3 2026 results showing an adjusted loss and a large IPR&D charge tied to civorebrutinib.
- companyEverest Medicines
Licensing and collaboration partner referenced as the source of the civorebrutinib-related IPR&D expense.
- analyst_firmLeerink Partners
Cut Travere’s price target to $67 from $78, compounding post-earnings pressure.
- personEric Dube
CEO who sold 243,735 shares in mid-October at an average price of $53.82.
